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The oocyte-secreted factors bone morphogenetic protein 15 (BMP15) and growth 
differentiation factor 9 (GDF9) interact functionally and it is hypothesised that this 
interaction may be mediated by formation of a GDF9:BMP15 heterodimer, termed cumulin. 
GDF9 and BMP15 regulate folliculogenesis and ovulation rate, and have been shown to 
regulate inhibin and activin, local regulators of folliculogenesis. The objective of this study 
was to determine if cumulin regulates granulosa cell inhibin and activin production, and if 
this requires cooperation with FSH. Human granulosa-lutein (hGL) cells collected from IVF 
patients were cultured ± FSH with various forms of recombinant cumulin (native and 
cysteine mutants, and with/without the pro-domains), and cysteine mutant GDF9 or BMP15. 
Messenger RNA expression of the subunits of inhibins/activins (INHA, INHBA, INHBB) and 
secretion of inhibin A, inhibin B, and activin B were measured. Mature- and pro-forms of 
cumulin stimulated comparable INHBB mRNA expression and secretion of inhibin B and 
activin B, whereas GDF9 or BMP15 exhibited no effect. Cumulin, but not GDF9 or BMP15, 
interacted synergistically with FSH to increase INHBB mRNA and inhibin B expression. FSH 
markedly stimulated INHA, which encodes the α subunit of inhibin A/B, and suppressed 
activin B. Cumulin ± FSH did not significantly alter inhibin A. Together these data 
demonstrate that cumulin, but not GDF9 or BMP15, exerts paracrine control of FSH-induced 
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regulation of inhibin B and activin B. The pro-domains of cumulin may have a minimal role 
in its actions on granulosa cells. 
INTRODUCTION 
The pituitary gonadotropins, FSH and LH stimulate folliculogenesis by promoting growth 
and differentiation of the granulosa cells of the ovarian follicle1. In addition, local growth 
factors produced by ovarian follicular cells and the oocyte itself regulate follicle development 
through their direct actions on granulosa cells and also indirectly by modulating gonadotropin 
secretion. Belonging to the TGFβ superfamily, activins and inhibins exert opposing effects on 
pituitary FSH production and secretion, whereby they stimulate and perturb FSH production, 
respectively 2. FSH and LH actions in the follicle are also regulated by the oocyte-secreted 
growth factors; growth differentiation factor 9 (GDF9) and bone morphogenetic protein 15 
(BMP15), and this interaction between gonadotropins and oocyte paracrine factors is thought 
to underpin the basic physiological mechanism regulating the species-specific ovulation rate 
and fecundity in mammals 3-5.  
Over the past decade it has become clear that the oocyte plays a major role in regulating 
follicle development and modulating its own follicular microenvironment by the secretion of 
paracrine growth factors that act on the follicle somatic cells 6. GDF9 and BMP15 are two 
closely related paralogs of the TGFβ superfamily that are principally produced by the oocyte 
in females 7. These two oocyte-secreted factors act on surrounding granulosa cells to regulate 
their growth and differentiation, affecting folliculogenesis and oocyte development and 
maturation. GDF9 and BMP15 are essential for female fertility, and genetic mutations in 
these growth factors alter follicle development and thus reproductive potential in mammals 
(reviewed by Juengel, McNatty 8). GDF9 and BMP15 signal via BMPRII/ALK cell surface 
receptors to phosphorylate intracellular SMAD proteins that regulate the transcription of 
several genes 4.  
Like all TGFβ superfamily ligands, GDF9 and BMP15 are produced as pro-mature 
proteins and require proteolytic cleavage by furin-like proteases to release the N-terminal 
pro-domain from the receptor binding C-terminal mature domain to become bioactive 9,10. 
However, GDF9 and BMP15 are unusual TGFβ ligands as they lack the conserved fourth 
cysteine residue required to make the intersubunit disulphide bond that links TGFβ ligand 
dimers covalently, and therefore they form non-covalent dimers 11. Due to their non-covalent 
dimer interaction, shared spatiotemporal expression pattern in the oocyte, close structural 
homology, and their co-immunoprecipitation, it is speculated that GDF9 and BMP15 can 
physically interact, likely to form a GDF9:BMP15 heterodimer, called cumulin 4,12-14. 
Functional studies have shown potent GDF9+BMP15 synergistic responses in granulosa cell 
proliferation, progesterone and inhibin α subunit protein production, and SMAD activity in 
vitro 14-16, and such GDF9+BMP15 synergism is thought to be due to the formation of a 
structural heterodimer of GDF9 and BMP15, i.e. cumulin 12. Recently, we synthesised 
cumulin, modelled its receptor interactions and signaling, demonstrated its high potency on 
granulosa cells, and hypothesized a central role for cumulin in determining the low ovulation 
rate phenotype in mammals such as humans 12.  
Due to its recent characterization, most aspects of cumulin’s molecular form and cellular 
and physiological functions require elucidation.  Nonetheless, new evidence suggests cumulin 
has significant potential for improving the treatment of female infertility. Pro-cumulin is able 
to improve the quality and developmental competence of pig and human oocytes matured in 
vitro 12,17. Interestingly, these improvements were only elicited by the pro-cumulin form and 
not by the highly bioactive mature form which has no pro-region 12. This suggests that the 
GDF9 and BMP15 pro-domains in cumulin play an important role in its function 18,19. Mouse 
pro-GDF9 induces inhibin B production by human granulosa-lutein cells (20) and pro-GDF9 
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and pro-BMP15 potently synergize to promote total inhibin (including the bioinactive free α 
subunit monomer) production by sheep granulosa cells 15, leading us to hypothesize a role for 
pro-cumulin in the inhibin-activin system in granulosa cells.  
The objectives of this study were to examine the role of cumulin, including the role of its 
pro-domains, and its cooperative effects with FSH, on granulosa cell production of inhibins 
and activins. To do this, various recombinant forms of cumulin dimers that were covalently 
or non-covalently linked, with and without their pro-domain, were generated and their effect 
on human granulosa-lutein cell production of inhibin A and B and activin B were examined. 
MATERIALS AND METHODS 
Human granulosa-lutein cell purification and culture 
This study was approved by IVF Australia Ethics Committee (approval number 100). Human 
granulosa-lutein (hGL) cells were purified from follicular aspirates of women undergoing 
transvaginal oocyte retrieval following controlled ovarian stimulation for in vitro fertilisation. 
Follicle aspiration was performed 36 hours after administration of recombinant human 
chorionic gonadotropin (Ovidrel) to induce final oocyte maturation. For each experiment, 
cells from at least four patients were pooled and no patient samples were excluded from the 
study. Cells were prepared using a modified version of the methods described by Ferrero et 
al. (2012)21 and Chang et al. (2013)22. Briefly, follicular fluid was passed through a 70µm cell 
strainer (Corning, Corning, USA) that was back washed with media to collect cell aggregates, 
which were recovered following centrifugation at 400xg for 10 min. The cell pellet was 
resuspended in HEPES-buffered αMEM (Gibco, Waltham, USA) containing 0.3% BSA 
(CellMaxx, MP Biomedicals, New Zealand) and hyaluronidase (100 mg/mL), followed by 
centrifugation at 1000xg for 2 min. The pellet was then resuspended in 4ml media and 
layered onto 8ml of Ficoll-Paque Premium 1.084 (GE Healthcare, Chicago, USA), 
centrifuged at 1000xg for 25 min and the interphase was collected. Cells were washed in 
DMEM (Gibco, Waltham, USA) containing 5% FBS (Gibco, Waltham USA) and 1% (v/v) 
Antibiotic Antimycotic Solution (Gibco, Waltham USA) and plated in the same media at a 
density of 3x105 cells per well in 1mL in a 24 well plate (Costar, Corning, USA). Cells were 
incubated for 5 days at 37ºC in 5% CO2 with media changes every second day to re-derive 
FSH-sensitive granulosa cells as previously described23-25. After 120 h, cells were washed 
once with 1 mL DMEM containing Antibiotic Antimycotic Solution and 0.3% BSA, and 
treated for 24 h with 500 µL of this media containing the various growth factors (see next 
section and Figure 1) ± 50 mIU/mL recombinant human FSH (Follitropin-β, Puregon, 
Organon, Oss, The Netherlands), as indicated in the text and figure legends. Cell pellets or 
conditioned media were then used for qPCR or ELISA assays, respectively.  
Recombinant proteins  
GDF9, BMP15 and cumulin in their pro-mature dimeric forms and mature cumulin (Figure 1 
and Table 1) were used in this study. A pro-form refers to a dimeric complex of 
proteolytically cleaved pro- and mature-domain forms (Fig. 1A-D), whereas the mature form 
is a dimer lacking the pro-domain (Fig. 1E). As GDF9 and BMP15 exist as non-covalent 
dimers lacking the fourth cysteine residue common in TGFβ superfamily members, Ser418 of 
GDF9 and Ser356 of BMP15 were modified by substituting to cysteines, as previously 
described, to generate stabilised covalent-linked dimers of GDF9, BMP15 and cumulin that 
cannot dissociate 12,16. These covalent proteins are indicated by the yellow link on the mature 
dimer in figures 1A-C, 1E. All proteins were produced in-house and human protein 
sequences were used. 
Production and purification of non-covalent pro-cumulin and covalent mature cumulin 
(Fig. 1D-E) was carried out as previously described 12. Their bioactivities were assessed 
based on their ability to activate SMAD signalling pathways as measured by SMAD-
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responsive luciferase assays (A3-luciferase and BRE-luciferase) in the COV434 human 
granulosa cell line, as previously described 12.  
Production and purification of pro-mature complexes containing covalently stabilised 
dimeric mature domains (pro-GDF9S418C, pro-BMP15S356C and covalent pro-cumulin; Fig. 
1A-C) were produced similarly to that described previously 12. Differences in methodology 
included production of recombinant proteins by transient transfection of HEK-293T cells 
using polyethylenimine-MAX (PEI-MAX) (Polysciences, Warrington, PA). When producing 
pro-GDF9S418C or pro-BMP15S356C homodimers, one plasmid type was transfected containing 
the respective cDNA. To produce the heterodimer covalent pro-cumulin, plasmids for both 
GDF9S418C and BMP15S356C were co-transfected. Protein purification was undertaken by 
cobalt-based immobilized metal affinity chromatography (Co-IMAC) using HisPur™ Cobalt 
Resin (Thermo Fisher Scientific, Waltham, MA). Bound proteins were eluted from Co-IMAC 
resin using elution buffer (50 mM phosphate buffer, 300 mM NaCl, 200 mM imidazole, pH 
7.4). Imidazole was removed by dialysis against binding buffer (50 mM phosphate buffer, 
300 mM NaCl, pH 7.4) using Slide-A-Lyzer® MINI Dialysis Devices (2 mL 3.5K MW Cut-
off; Thermo Fisher Scientific, Waltham, MA) according to the manufacturer’s guidelines. 
Activation of SMAD signalling reporters, A3-luciferase and BRE-luciferase, was assessed in 
the COV434 human granulosa cell line as previously described 12.  
Real-time RT-PCR 
Total RNA was isolated from cell pellets using the Qiagen microRNEasy kit (Qiagen, 
Germany) per the manufacturer’s protocol. Total RNA was measured using a NanoDrop 
Spectrophotometer ND-1000 (Thermo Fisher Scientific, Waltham, USA). First-strand cDNA 
was synthesised using Superscript III reverse transcriptase and random primers (Invitrogen, 
Waltham, USA). Real-time RT-PCR was performed in duplicate using gene primers 
(GeneWorks, Australia; Table 2) on a Roche LightCycler 480 (Roche, Basel, Switzerland). 
Controls, including the absence of cDNA template or the reverse transcriptase enzyme in 
otherwise complete reactions showed no product amplification or genomic DNA 
contamination. Target gene expression was normalised to GAPDH expression. Using the 
statistical program BestKeeper, GAPDH was determined as a stable housekeeping gene with 
a SD (±Ct) and CV (%Ct) of 0.43 and 2.37, respectively, when its expression was measured 
across 5 different pools of hGL cells treated ± pro-GDF9, pro-BMP15, and pro-cumulin, all ± 
FSH. PCR data is expressed as the raw gene expression level using the 2-(∆CT) method 26. 
Inhibin A, B and Activin B ELISAs 
Inhibin A and B are heterodimers of a common α-subunit bound covalently to a βA- or βB-
subunit, respectively. The pro-forms of inhibin A and inhibin B were measured in hGL cell 
conditioned media using immunoassays as detailed by Walton et al. (2013)27  that utilise 
antibodies to the α-, βA- and βB-subunits of inhibin.  
 Activin B is a homodimer of the βB-subunit. Total activin B was measured in hGL cell 
conditioned media using the Ansh Labs commercial ELISA kit (Ansh Labs, Webster, TX) 
according to the manufacturer’s instructions, or using an in-house ELISA possessing similar 
sensitivity and specificity for human activin B, as previously described 28. Samples that gave 
readings below the limit of quantification (LOQ) of the assay were assigned values of 
LOQ/2.  
Statistical analyses 
Results are presented as the mean ± SEM. The number of independent pools of granulosa 
cells tested for each experiment is indicated in the figure legends. Statistical analyses were 
performed using GraphPad Prism 7.02 software and differences were considered to be 
significant at P ≤0.05. Data that were not normally distributed were transformed before 
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5
analysis using log transformation. One-way ANOVA or two-way ANOVA (where two 
independent variables were tested) with multiple comparisons tests were used. 
RESULTS 
Cumulin stimulates granulosa cell inhibin B production 
Covalent mature cumulin and non-covalent pro-cumulin each dose-dependently increased 
INHBB mRNA expression (Fig. 2A), which encodes a βB-subunit that in homodimeric form 
makes activin B or as a heterodimer with an α-subunit forms inhibin B. INHBA or INHA 
mRNA expression (encoding the βA- and α-subunits, respectively) was unaffected by 
treatment with either form of cumulin (Fig. 2B-C). Covalent pro-cumulin stimulated a 
significant dose-dependent increase in INHBB expression relative to no treatment control, 
however treatment with either of the homodimers, covalent pro-GDF9 and covalent pro-
BMP15, did not affect INHBB mRNA expression at any dose tested (Fig. 3A). None of the 
proteins elicited a significant increase in INHBA (Fig. 3B) or INHA (Fig. 3C) mRNA 
expression, except INHBA which was significantly higher than control following exposure to 
12.5 ng/mL covalent pro-cumulin (Fig. 3B).  
Cumulin and FSH exert dual control of inhibin B production 
FSH, a known driver of inhibin secretion in granulosa cells 29  gave a marked 15-fold 
increase in INHA mRNA expression (Fig. 4A). The FSH effect on INHA mRNA expression 
was further significantly (P<0.05) enhanced by co-treatment with pro-BMP15, or pro-
cumulin but not pro-GDF9.  Pro-cumulin and FSH synergistically increased (i.e. the effect of 
both factors combined was greater than the sum of either factor alone) INHBB mRNA and 
inhibin B protein production (two-way ANOVA, P <0.05; interaction of main effects of FSH 
and growth factor), whilst pro-GDF9 ± FSH and pro-BMP15 ± FSH had no significant effect 
(Figs. 4B, C). A trend in interactive effect between FSH and treatment on activin B was 
observed (P =0.07; Fig. 4D). Activin B production was upregulated by pro-cumulin, but only 
in the absence of FSH, whilst pro-GDF9 ± FSH and pro-BMP15 ± FSH had no significant 
effect on activin B (Fig. 4D).  
The pro-domain does not affect hGL cell responsiveness to cumulin 
As the pro-domains of GDF9, BMP15 and cumulin are required for the stimulatory effect of 
these growth factors on oocyte quality, as measured by an oocyte’s capacity to support 
development to the blastocyst stage 12,18,19, a comparison was made between pro-cumulin and 
mature cumulin. Whilst pro- and mature-cumulin both significantly (two-way ANOVA, P 
≤0.01; main effects) promoted INHBB, inhibin B and activin B levels, no significant 
difference was observed between them in terms of the extent of stimulation at the tested dose 
(Fig. 5). Overall, FSH stimulated inhibin B production while suppressing activin B (2-way 
ANOVAs, P <0.01; main effects of FSH) (Fig. 5B, 5C).  
Inhibin A production is not regulated by cumulin 
Pro-cumulin in the presence of FSH stimulated INHBA mRNA expression whilst mature 
cumulin did not (Fig. 5D). Inhibin A secretion in granulosa cell cultures was unaffected by 
FSH, by either form of cumulin or by the interaction of FSH and cumulin (Fig. 5E).  
DISCUSSION 
The nature of the native forms of GDF9 and BMP15, and whether they occur physiologically 
as the heterodimer cumulin, remains unclear as they are yet to be isolated from biological 
fluids. However, there is substantial evidence of synergistic interactions between GDF9 and 
BMP15, and a prominent hypothesis in the field is that such synergism is mediated by a 
heterodimer molecule, cumulin, consisting of at least one subunit of GDF9 and BMP15 12. In 
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this study, we demonstrate that cumulin regulates inhibin B and activin B production in 
human granulosa-lutein cells. We bioengineered and purified wild-type non-covalent 
cumulin, as well as covalent dimers containing an introduced inter-subunit disulphide bridge. 
Pro- and mature-cumulin induced comparable expression of INHBB, inhibin B, and activin B 
in hGL cells, whereas covalent pro-GDF9 or pro-BMP15 elicited no effect. This supports that 
GDF9 and BMP15 linkage results in distinct activation of gene expression, relative to GDF9 
or BMP15 alone.  
These observations are in line with a previous study showing synergistic upregulation of 
total inhibin (including the bioinactive free α subunit monomer) in rat granulosa cells when 
murine or ovine GDF9 conditioned media was added together with ovine BMP15 conditioned 
media, but no effect was seen when either GDF9 or BMP15 conditioned media were used in 
isolation 15. Moreover, others have reported a negative effect of GDF9 or BMP15 alone on 
inhibin production. Human BMP15 had no effect on INHA, INHBA, and INHBB mRNA 
expression in rat granulosa cells, and it decreased mRNA expression of these subunits in the 
presence of FSH 30. Mouse GDF9 also inhibited total inhibin production in ovine and bovine 
granulosa cells 31, and E.coli expressed human GDF9 had no effect on inhibin A and B 
production in hGL cells 32. In contrast to these studies, GDF9 and BMP15 individually have 
been reported to regulate the inhibin system in granulosa cells. Pulkki et al. (2011, 2012) 33,34 
demonstrated that purified mature human BMP15 was a stimulator of inhibin B production in 
hGL cells. Roh et al. (2003) reported upregulation of inhibin A and inhibin B in rat granulosa 
cells in response to mature rat GDF9, an effect that was enhanced by FSH 35. Kaivo-Oja et al. 
(2003) also reported stimulation of inhibin B secretion by mature rat GDF9 in hGL cells 20. 
These discrepancies in the literature on the roles of GDF9 and BMP15 in regulating inhibin 
production are likely due to methodological differences such as the use of different granulosa 
cell types from different species at different stages of folliculogenesis, and the large 
variability in the construct and purity of the in-house produced growth factors used. Many of 
the early studies in the field used unpurified growth factors including raw conditioned media 
and this is likely to be a significant contributor to the discrepancy in reporting. Indeed, this 
issue persists in the case of cumulin as it is newly described and there are just three 
publications to date 12,13,36. In this study we generated highly purified forms of cumulin, 
including novel variants such as covalent pro-cumulin, which has enabled further scrutiny of 
its role in regulating granulosa cell function. Overall, the findings of this study demonstrate 
that cumulin regulates granulosa cell inhibin B and activin B production, and the homodimers 
GDF9 or BMP15 alone do not. There was no pronounced effect of cumulin on inhibin A 
production despite the stimulatory effect on inhibin B. This is in line with previous work 
where two other Smad2/3-activating members of the TGFβ superfamily, TGFβ1 and activin 
A, were shown to have a more marked stimulatory effect on inhibin B than on inhibin A 
production in rat granulosa cells 37. 
FSH is a well-established stimulator of granulosa cell inhibin subunit gene expression and 
inhibin A and B production 37,38. FSH markedly upregulated INHA expression that encodes 
the α subunit of inhibin A/B, and expression was further enhanced by BMP15 and cumulin. 
Moreover, a synergistic interaction was seen between FSH and covalent pro-cumulin in 
upregulating inhibin B. FSH also decreased activin B production. Hence, we postulate that 
cumulin and FSH synergistically increase inhibin B production by increasing the availability 
of the βB and α subunits, respectively, leading to heterodimerisation of the α and βB subunits 
to form inhibin B. This occurs at the expense of activin B production since activin B is 
comprised of two βB subunits. No synergistic interaction was observed between FSH and 
either GDF9 or BMP15 alone, providing evidence to support the hypothesis that the basis for 
their regulation of the inhibin-activin system is through the formation of cumulin; the use of 
covalently linked mutant dimers of cumulin provides further support that they can act as a 
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functional dimeric unit. Whether cumulin exists naturally as a free dimeric entity, or GDF9 
and BMP15 form a heterodimer at the receptor level remains unclear. Using Western blotting 
procedures, Heath et al. (2017) recently reported that the predominate forms of GDF9 and 
BMP15 secreted by ovine and bovine oocytes were cleaved and uncleaved pro-mature 
monomers, and hypothesised that these monomers form a GDF9:BMP15 heterodimer at the 
receptor level 36. 
Previous investigation into the effects of cumulin on oocyte quality showed that 
cumulin’s pro-domain was important for cumulin to elicit an increase in subsequent embryo 
yield of in vitro matured porcine cumulus-oocyte complexes 12. This supported previous 
findings that pro-BMP15, but not mature BMP15 or mature GDF9, improve oocyte quality 
18,19
, suggesting that the pro-domain plays an important role in its function on cumulus cells. 
Hence we investigated the effect of the cumulin pro-domain on the inhibin-activin system 
using cumulin forms with and without the pro-domain. Mature covalent cumulin and non-
covalent pro-cumulin elicited comparable expression levels of INHBB, inhibin B and activin 
B, suggesting that the disulphide link and pro-domain do not affect granulosa cell 
responsiveness to cumulin. It is intriguing that the pro-domain plays a crucial functional role 
on the cumulus-oocyte complex but not on granulosa cells. The current hypothesis 
underpinning this is that the pro-domains of GDF9/BMP15/cumulin interact with the 
specialised heparin-sulphated proteoglycans of the cumulus-oocyte complex facilitating in 
some manner distinct ligand-receptor signalling cascades between the two cell types 39.  
There is compelling genetic evidence that paracrine signals from the oocyte in the form of 
GDF9 and BMP15 (and possibly cumulin), constitute key regulators of folliculogenesis, 
ovulation rate and fecundity in mammals 4. This notion is bolstered by the results of the 
current study whereby cumulin and FSH interact to enhance inhibin B production at the 
expense of activin B, as inhibin is a key endocrine regulator of FSH. In humans, inhibin B is 
the predominate form of inhibin/activin produced by granulosa cells in the early follicular 
phase 40. The current results suggest that oocyte paracrine signals, likely in the form of 
GDF9/BMP15/cumulin, cooperate with FSH to induce inhibin B during the follicular phase, 
which in turn feeds back to suppress pituitary FSH secretion, which limits the growth of 
multiple Graafian follicles and hence the ovulation quota. Oocyte paracrine signals including 
cumulin may have different effects on granulosa cells from other stages of folliculogenesis, 
e.g. inhibin A or activin production may be favoured. Oocyte cumulin-mediated enhancement 
of inhibin and corresponding antagonism of circulating FSH may be a feature of low-
ovulation phenotype mammals such as humans, as oocytes of polyovular mammals such as 
mice produce little BMP15 41 and hence presumably little cumulin 12. Consequently, it can be 
speculated that the cooperative regulation of inhibin B by cumulin and FSH may play a role 
in regulating folliculogenesis and fecundity in women. 
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subunit disulphide bridge are shown with a yellow link between the mature dimers (A-C, E). 
Human pro-GDF9 is naturally latent (A). 
Figure 2: Dose response of pro-cumulin and mature cumulin on inhibin A and B 
subunit production. Human granulosa-lutein cells were treated for 24 h with non-covalent 
pro-cumulin or covalent mature cumulin (cumulins:c) at varying concentrations. Expression of 
INHBB, INHBA, and INHA mRNA was measured. Data represent mean ± SEM of 5 
independent granulosa cell pools. ** P ≤0.01, *** P ≤0.001 vs control (0 ng/mL) for both 
pro-cumulin and mature cumulin treatments at the indicated dose. # P <0.05 vs control (0 
ng/mL) for pro-cumulin. 
Figure 3: Comparative effect of pro-cumulin, pro-GDF9 and pro-BMP15 on inhibin 
subunit mRNA expression. Human granulosa-lutein cells were treated for 24 h with 
covalent forms of pro- cumulin, pro-GDF9 or pro-BMP15 at varying concentrations. 
Expression of INHBB, INHBA, and INHA mRNA was measured. Data represent mean ± SEM 
of 7 independent granulosa cell pools. * P ≤0.05, ** P ≤0.01, *** P ≤0.001 vs control (0 
ng/mL) for pro-cumulin.  
Figure 4: The interactive effects of FSH and cumulin on inhibin B and activin B 
production. Human granulosa-lutein cells were treated for 24 h without (control) or with 50 
ng/mL covalent pro-GDF9, pro-BMP15 or pro-cumulin, all ± 50 mIU/mL FSH. Cellular 
mRNA expression of INHBB and INHA, as well as secreted inhibin B and activin B into 
conditioned media were measured. Data represent mean ± SEM of 5 independent granulosa 
cell pools. G*, significant main effect of growth factor by two-way ANOVA; F*, significant 
main effect of FSH by two-way ANOVA; GxF*; significant main effect interaction between 
growth factor and FSH by two-way ANOVA. ns, no significant difference; Bars within a 
graph not sharing a common letter are statistically different (P ˂0.05, multiple comparisons 
test). 
Figure 5: Effect of the cumulin pro-domain on inhibin A, inhibin B and activin B 
production. Human granulosa-lutein cell INHBB and INHBA mRNA expression (n=4), 
inhibin B (n=3), inhibin A (n=3), and activin B (n=5) protein secretion were measured 
following 24 h treatment with non-covalent pro-cumulin (50 ng/mL) or covalent mature 
cumulin (50 ng/mL), all ± FSH (50 mIU/mL). Bars within a graph not sharing a common 
letter are statistically different (-FSHa-b, +FSHx-y; P ˂0.05).    
Table1: Description of the purified recombinant growths factors used in this study. 
Protein Covalent Pro- domain 
CumulinS418C, S356C  X 
Pro-cumulin X  
Pro-cumulinS418C, S356C   
Pro- GDF9S418C   
Pro-BMP15S356C   
Table 2: PCR primer sequences used for real-time RT-PCR 
Gene GenBank accession Forward primer (5’- 3’) Reverse primer (5’- 3’) 
INHA NM_002191.2 GTCTCCCAAGCCATCCTTTT TGGCAGCTGACTTGTCCTC 
INHBA NM_002192.2 AGCTCAGACAGCTCTTACCAC CAAATTCTCTTTCTGGTCCCC 
INHBB NM_002193.3 ATCAGCTTCGCCGAGACA GCCTTCGTTGGAGATGAAGA 
GAPDH NM_002046.3 CGCCCCACTTGATTTTGG ATGGATCCCATCACCATCTT 
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